Alzheimer's disease (AD) is a neurodegenerative disorder characterized by pathogenesis involving numerous factors. Recent research has highlighted the significant role of autoimmunity in the initiation and progression of AD, with autoantibodies emerging as a pivotal area of investigation. Nevertheless, the influence of autoantibodies in AD is marked by substantial heterogeneity, they may either mitigate disease progression by clearing pathogenic protein aggregates or exacerbate the pathological process through mechanisms such as the activation of inflammatory responses or the induction of neuronal damage.
Objective
This review aims to synthesize the various roles of autoantibodies in AD, examine the factors that influence their functions, and assess their potential application in precision immunotherapy.
Methods
PubMed and Web of Science databases were searched for English-language papers (2015–2025). Peer-reviewed human, animal and cell studies, systematic reviews and meta-analyses were screened independently by two reviewers.
Results
A total of 87 studies were selected for inclusion, spanning human, animal, and cellular research. The findings indicated that certain autoantibodies, such as those targeting amyloid-β, tau, or 4-hydroxynonenal, may confer neuroprotective effects. Conversely, other autoantibodies, including those against BACE1, aquaporin-4, or HuD, may exacerbate AD pathology. Importantly, some autoantibodies were found to exhibit dual roles, contingent upon their specific modifications or the context of the disease.
Conclusions
Autoantibodies constitute a double-edged immune axis in AD. Their impact hinges on antigen class, disease stage, isotype affinity and glycosylation. Precision strategies—like CAAR-T cell therapy, glycosylation modulation, and affinity optimization—offer therapeutic promise but require further validation.
LuoRSuLYLiG, et al.Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy2020; 16: 52–69.
2.
Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet2024; 403: 2204–2256.
3.
JiaJWeiCChenS, et al.The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement2018; 14: 483–491.
4.
MonteiroARBarbosaDJRemiãoF, et al.Alzheimer's disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol2023; 211: 115522.
5.
LimBPrassasIDiamandisEP. Alzheimer disease pathogenesis: the role of autoimmunity. J Appl Lab Med2021; 6: 756–764.
6.
NimmerjahnAKirchhoffFHelmchenF. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science2005; 308: 1314–1318.
7.
NorrisGTKipnisJ. Immune cells and CNS physiology: microglia and beyond. J Exp Med2019; 216: 60–70.
8.
VennetiSWileyCAKoflerJ. Imaging microglial activation during neuroinflammation and Alzheimer's disease. J Neuroimmune Pharmacol2009; 4: 227–243.
9.
SinghD. Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease. J Neuroinflammation2022; 19: 206.
10.
FangLJiaoBLiuX, et al.Specific serum autoantibodies predict the development and progression of Alzheimer's disease with high accuracy. Brain Behav Immun2024; 115: 543–554.
11.
WangYRZengXQWangJ, et al.Autoantibodies to BACE1 promote Aβ accumulation and neurodegeneration in Alzheimer's disease. Acta Neuropathol2024; 148: 57.
12.
ZhuFHePJiangW, et al.Astrocyte-secreted C3 signaling impairs neuronal development and cognition in autoimmune diseases. Prog Neurobiol2024; 240: 102654.
13.
Renuka SanotraMHuangWCSilverS, et al.Serum levels of 4-hydroxynonenal adducts and responding autoantibodies correlate with the pathogenesis from hyperglycemia to Alzheimer's disease. Clin Biochem2022; 101: 26–34.
14.
van der HovenJvan HummelAPrzybylaM, et al.Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice. Sci Rep2020; 10: 13845.
15.
ChatanakaMKSohaeiDDiamandisEP, et al.Beyond the amyloid hypothesis: how current research implicates autoimmunity in Alzheimer's disease pathogenesis. Crit Rev Clin Lab Sci2023; 60: 398–426.
16.
HeCYTianDYChenSH, et al.Elevated levels of naturally-occurring autoantibodies against the extracellular domain of p75NTR aggravate the pathology of Alzheimer's disease. Neurosci Bull2023; 39: 261–272.
17.
ShimSMKohYHKimJH, et al.A combination of multiple autoantibodies is associated with the risk of Alzheimer's disease and cognitive impairment. Sci Rep2022; 12: 1312.
18.
KokkonenNHerukkaSKHuilajaL, et al.Increased levels of the bullous pemphigoid BP180 autoantibody are associated with more severe dementia in Alzheimer's disease. J Invest Dermatol2017; 137: 71–76.
19.
BartosAFialováLSvarcováJ, et al.Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. J Neuroimmunol2012; 252: 100–105.
20.
NageleEHanMDemarshallC, et al.Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One2011; 6: e23112.
21.
San Segundo-AcostaPMontero-CalleAFuentesM, et al.Identification of Alzheimer's disease autoantibodies and their target biomarkers by phage microarrays. J Proteome Res2019; 18: 2940–2953.
22.
LimBTsolakiMBatruchI, et al.Putative autoantibodies in the cerebrospinal fluid of Alzheimer's disease patients. F1000Res2019; 8: 1900.
23.
XieZGaoYTianL, et al.Pemphigus and pemphigoid are associated with Alzheimer's disease in older adults: evidence from the US Nationwide inpatient sample 2016–2018. BMC Geriatr2023; 23: 872.
24.
HansenNTeegenBHirschelS, et al.Case report: mixed dementia associated with autoantibodies targeting the vesicular glutamate transporter 2. Front Psychiatry2023; 14: 1227824.
25.
HansenNMalchowBTeegenB, et al.Case report: Alzheimer's dementia associated with cerebrospinal fluid neurochondrin autoantibodies. Front Neurol2022; 13: 879009.
26.
WirenfeldtMBabcockAAVintersHV. Microglia - insights into immune system structure, function, and reactivity in the central nervous system. Histol Histopathol2011; 26: 519–530.
27.
NutmaEWillisonHMartinoG, et al.Neuroimmunology - the past, present and future. Clin Exp Immunol2019; 197: 278–293.
28.
JevticSSengarASSalterMW, et al.The role of the immune system in Alzheimer disease: etiology and treatment. Ageing Res Rev2017; 40: 84–94.
29.
LongCFrittsABroadwayJ, et al.Neuroinflammation: a driving force in the onset and progression of Alzheimer's disease. J Clin Med2025; 14: 331.
30.
ZhangSGaoZFengL, et al.Prevention and treatment strategies for Alzheimer's disease: focusing on microglia and astrocytes in neuroinflammation. J Inflamm Res2024; 17: 7235–7259.
31.
ZhangFJiangL. Neuroinflammation in Alzheimer's disease. Neuropsychiatr Dis Treat2015; 11: 243–256.
32.
XiaoZXMillerJSZhengSG. An updated advance of autoantibodies in autoimmune diseases. Autoimmun Rev2021; 20: 102743.
33.
GrönwallCVasJSilvermanGJ. Protective roles of natural IgM antibodies. Front Immunol2012; 3: 66.
34.
PalmaJTokarz-DeptułaBDeptułaJ, et al.Natural antibodies - facts known and unknown. Cent Eur J Immunol2018; 43: 466–475.
35.
ElkonKBSilvermanGJ. Naturally occurring autoantibodies to apoptotic cells. Adv Exp Med Biol2012; 750: 14–26.
36.
PrüssH. Autoantibodies in neurological disease. Nat Rev Immunol2021; 21: 798–813.
37.
DuYDodelRHampelH, et al.Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology2001; 57: 801–805.
38.
MusicMSoosaipillaiABatruchI, et al.A proteome-wide immuno-mass spectrometric identification of serum autoantibodies. Clin Proteomics2019; 16: 25.
39.
LinJZhengDTianD, et al.High frequency of autoantibodies in COVID-19 patients with central nervous system complications: a multicenter observational study. Mol Neurobiol2024; 61: 8414–8424.
40.
SanotraMRKaoSHLeeCK, et al.Acrolein adducts and responding autoantibodies correlate with metabolic disturbance in Alzheimer's disease. Alzheimers Res Ther2023; 15: 115.
41.
WangYRWangMTZengXQ, et al.Associations of naturally occurring antibodies to presenilin-1 with brain amyloid-β load and cognitive impairment in Alzheimer's disease. J Alzheimers Dis2022; 90: 1493–1500.
42.
HansenNHirschelSTeegenB, et al.Preserved visuoconstruction in patients with Alzheimer's pathology and anti-neural autoantibodies: a case control study. Front Dement2022; 1: 975851.
43.
HansenNBartelsCStöckerW, et al.Impaired verbal memory recall in patients with axonal degeneration and serum glycine-receptor autoantibodies-case series. Front Psychiatry2021; 12: 778684.
44.
WangTXieXXJiM, et al.Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin. Neuropharmacology2016; 105: 561–576.
45.
PiazzaFCaminitiSPZeddeM, et al.Association of microglial activation with spontaneous ARIA-E and CSF levels of anti-aβ autoantibodies. Neurology2022; 99: e1265–e1277.
46.
GaikwadNSarwadeRHalderS, et al.Hud regulates apoptosis in N2a cells by regulating Msi2 expression. PLoS One2024; 19: e0315535.
47.
KarczewskiPHempelPBimmlerM. Role of alpha1-adrenergic receptor antibodies in Alzheimer's disease. Front Biosci (Landmark Ed)2018; 23: 2082–2089.
48.
GoldwaserELAcharyaNKWuH, et al.Evidence that brain-reactive autoantibodies contribute to chronic neuronal internalization of exogenous amyloid-β1–42 and key cell surface proteins during Alzheimer's disease pathogenesis. J Alzheimers Dis2020; 74: 345–361.
49.
KronimusYAlbusAHasenbergM, et al.Fc N-glycosylation of autoreactive Aβ antibodies as a blood-based biomarker for Alzheimer's disease. Alzheimers Dement2023; 19: 5563–5572.
50.
VojdaniAVojdaniESaidaraE, et al.Reaction of amyloid-β peptide antibody with different infectious agents involved in Alzheimer's disease. J Alzheimers Dis2018; 63: 847–860.
51.
HenkelAWDittrichPSGroemerTW, et al.Immune complexes of auto-antibodies against A beta 1–42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients. Mol Psychiatry2007; 12: 601–610.
52.
NeffFWeiXNölkerC, et al.Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev2008; 7: 501–507.
53.
JianJMFanDYTianDY, et al.Naturally-occurring antibodies against Bim are decreased in Alzheimer's disease and attenuate AD-type pathology in a mouse model. Neurosci Bull2022; 38: 1025–1040.
54.
GrönwallCSilvermanGJ. Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease. J Clin Immunol2014; 34: S12–S21.
55.
Di DomenicoFPupoGGiraldoE, et al.Autoantibodies profile in matching CSF and serum from AD and aMCI patients: potential pathogenic role and link to oxidative damage. Curr Alzheimer Res2016; 13: 112–122.
56.
DaviesP. The neurochemistry of Alzheimer's disease and senile dementia. Med Res Rev1983; 3: 221–236.
57.
SkokMLykhmusO. The role of α7 nicotinic acetylcholine receptors and α7-specific antibodies in neuroinflammation related to Alzheimer disease. Curr Pharm Des2016; 22: 2035–2049.
58.
PapućEKurys-DenisEKrupskiW, et al.Can antibodies against glial derived antigens be early biomarkers of hippocampal demyelination and memory loss in Alzheimer's disease?J Alzheimers Dis2015; 48: 115–121.
59.
GrudenMADavidovaTBMalisauskasM, et al.Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta((25–35)) oligomers, S100b and neurotransmitters. J Neuroimmunol2007; 186: 181–192.
60.
McIntyreJARamseyCJGitterBD, et al.Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease. Autoimmunity2015; 48: 344–351.
61.
KnechtLDalsbølKSimonsenAH, et al.Autoantibody profiles in Alzheimer's, Parkinson's, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns. J Neuroinflammation2024; 21: 317.
62.
LiXWLiXXLiuQS, et al.Blood and cerebrospinal fluid autoantibody to aβ levels in patients with Alzheimer's disease: a meta-analysis study. J Mol Neurosci2020; 70: 1208–1215.
63.
SuZXieQWangY, et al.Abberant immunoglobulin G glycosylation in rheumatoid arthritis by LTQ-ESI-MS. Int J Mol Sci2020; 21: 2045.
64.
ZhouXMottaFSelmiC, et al.Antibody glycosylation in autoimmune diseases. Autoimmun Rev2021; 20: 102804.
65.
SeetDAllameenNATaySH, et al.Cognitive dysfunction in systemic lupus erythematosus: immunopathology, clinical manifestations, neuroimaging and management. Rheumatol Ther2021; 8: 651–679.
66.
ParkHYimDHOchirpurevB, et al.Association between dementia and systemic rheumatic disease: a nationwide population-based study. PloS One2021; 16: 11.
67.
JinTYHuangWCaoFZ, et al.Causal association between systemic lupus erythematosus and the risk of dementia: a Mendelian randomization study. Front Immunol2022; 13: 9.
68.
BarnhartMMChapmanMR. Curli biogenesis and function. Ann Rev Microbiol2006; 60: 131–147.
69.
NicastroLKde AndaJJainN, et al.Assembly of ordered DNA-curli fibril complexes during Salmonella biofilm formation correlates with strengths of the type I interferon and autoimmune responses. PLoS Pathog2022; 18: e1010742.
70.
PocevičiūtėDRothBSchultzN, et al.Plasma IAPP-autoantibody levels in Alzheimer's disease patients are affected by APOE4 status. Int J Mol Sci2023; 24: 3776.
71.
SimKYParkSHChoiKY, et al.High-throughput epitope profiling of antibodies in the plasma of Alzheimer's disease patients using random peptide microarrays. Sci Rep2019; 9: 4587.
72.
CaoHDuXZengR, et al.Effect of different Aβ aggregates as antigen on the measure of naturally occurring autoantibodies against amyloid-β40/42 in IVIG. Curr Alzheimer Res2019; 16: 1290–1299.
73.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
74.
LiLYKelesAHomeyerMA, et al.Antibodies in neurological diseases: established, emerging, explorative. Immunol Rev2024; 328: 283–299.
75.
ReinckeSMvon WardenburgNHomeyerMA, et al.Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell2023; 186: 5084–5097.e5018.
76.
OhSMaoXManfredo-VieiraS, et al.Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol2023; 41: 1229–1238.
77.
ChengQPelzATaddeoA, et al.Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies. Eur J Immunol2020; 50: 284–291.
78.
BettcherBMTanseyMGDorothéeG, et al.Peripheral and central immune system crosstalk in Alzheimer disease - A research prospectus. Nat Rev Neurol2021; 17: 689–701.
79.
BartschYCRahmöllerJMertesMMM, et al.Sialylated autoantigen-reactive IgG antibodies attenuate disease development in autoimmune mouse models of lupus nephritis and rheumatoid arthritis. Front Immunol2018; 9: 1183.
80.
PaganJDKitaokaMAnthonyRM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell2018; 172: 564–577.e513.
81.
DuanTTradtrantipLPhuanPW, et al.Affinity-matured ‘aquaporumab’ anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology2020; 162: 107827.
82.
AlbusAKronimusYNeumannS, et al.Effects of a multimerized recombinant autoantibody against amyloid-β. Neuroscience2021; 463: 355–369.
